A three-year U.K. project will investigate whether weight-shifting strategies, developed and tested using virtual reality, can help people with Parkinson’s disease to overcome freezing of gait — when patients feel like their feet are “glued” to the floor and can’t move forward. If these strategies prove successful in…
Parkinson’s UK is paving the way for a future clinical trial that will continue to test a naturally occurring protein, the glial cell line-derived neurotrophic factor or GDNF, as a potential therapy for slowing Parkinson’s disease progression. The new trial will follow a 2019 clinical study of…
Five genes appear to be involved in the onset and development of Lewy body dementia (LBD), a neurodegenerative disorder characterized by toxic protein clumps, known as Lewy bodies, inside brain cells, a study by a branch of the National Institutes of Health reported. Some of these genes are also associated…
A project investigating a complex formed by two key proteins involved in Parkinson’s disease development has received nearly $150,000 in funding from the Michael J. Fox Foundation for Parkinson’s Research (MJFF). The research team behind the project believes the interaction between these two proteins — LIMP-2…
Surgeons in Detroit have become the first U.S. team to implant the newest deep brain stimulation (DBS) system — Boston Scientific’s Vercise Genus — in a Parkinson’s disease patient. The device, smaller and thinner than previous models, aims to reduce movement symptoms associated with Parkinson’s by stimulating…
PS128, a probiotic sold by Bened Biomedical, eased symptoms of Parkinson’s disease as an add-on treatment to 25 patients in a pilot clinical study, the company announced. Probiotics are live microorganisms that, when consumed, are thought to improve overall health. PS128 is a strain of the bacterial species Lactobacillus…
Blackfynn announced that its is acquiring the rights to a candidate Parkinson’s disease treatment that others gave up on but is thought ready to move into pivotal Phase 3 testing. Neither the investigative treatment nor the company that initially developed it — or other details of this acquisition — were…
Cure Parkinson’s is supporting AbFero Pharmaceuticals in its work to advance SP-420, a potential disease-modifying therapy for Parkinson’s disease that clears excess iron from the brain. The grant award supports further testing of AbFero’s lead compound in Parkinson’s models with a goal of moving it into clinical trials. SP-420, a next-generation iron…
Dosing has begun in a Phase 1 clinical trial testing Inhibikase Therapeutics’ investigational oral therapy IkT-148009 for Parkinson’s disease and related disorders in healthy volunteers. This first clinical trial (NCT04350177) is expected to enroll 112 healthy adults, ages 45 to 70, at a single site in…
People with low levels of lymphocytes, a type of white blood cell, may be at higher risk of Parkinson’s disease later in life, a large database study reports. While noting that low white blood cell counts may be a consequence of early Parkinson’s or of a yet unknown cause —…
Get regular updates to your inbox.
